# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹483.34 Cr** Q4 (+9% YoY) * **EBITDA:** **₹124.89 Cr** Q4 (+13.8% YoY) * **PAT:** **₹97.77 Cr** Q4 (+29.5% YoY) * **GST Refund:** **₹29 Cr** FY26 Total · **₹14.5 Cr** Q4 * **Royalty Payments:** **₹32 Cr** FY26 Total · **₹10 Cr** Q4 ## B. Revenue Growth * **Balanced Growth Profile:** Top-line expansion was characterized by a rare equilibrium between volume and value, contrasting with the previous year's volume-led but price-negative environment. * **Revenue Recognition:** Reported turnover figures were bolstered by the inclusion of GST refund amounts recognized during the quarter. ## C. Margins & Profitability * **Record Margin Drivers:** Achieved highest-ever EBITDA margins in Q4, primarily fueled by the realization of significant GST refunds from the **Udhampur unit** and internal cost-management directives. * **Expense Optimization:** Other expenses plummeted by **49%** in Q4 due to reduced "Dhanuka doctor" costs and increased field promotion support from principals. * **Pricing Power & Outlook:** Management intends to defend full-year margins against rising freight and raw material costs by passing price increases to customers and utilizing lower-cost carryover inventory. * **Non-Operating Gains:** Other income rose 20% YoY, aided by a **₹3 Cr** valuation uptick in **KisanKonnect** and the absence of prior-year investment provisions. ## D. Balance Sheet & Cash Flow * **Strategic Inventory Build:** Inventory levels are significantly higher as of March 31st, reflecting tactical procurement following the West Asia crisis and sluggish movement in the weedicides segment. * **Working Capital Discipline:** Receivables were successfully reduced by **4%** YoY, signaling tightened credit management despite the growth in operations. * **Royalty Headwinds:** While royalty income will continue into FY27, management anticipates levels may be slightly lower than the FY26 peak. --- # 2. Product & Segment Performance ## A. Key Figures * **Revenue Mix:** **41%** Insecticides · **31%** Herbicides · **14%** Fungicides · **14%** Others * **9-3 Product Contribution:** **26%** of total revenue * **Biologicals Revenue:** **₹70 Cr** FY26 (vs. ₹110 Cr FY25) ## B. Operating Segments & Portfolio Strategy * **Margin Dynamics:** Gross margins expanded and OpEx declined, though performance was tempered by slowing growth in herbicides and fungicides and lower contribution from new launches. * **Innovation Pipeline:** Leveraging partnerships with **10 global MNCs** to introduce technology-led chemistries; management aims to maintain the high-margin 9-3 product contribution at current levels even as the revenue base scales. * **Acreage Sensitivity:** Potential shifts toward soybean cultivation present an upside opportunity given the company's robust portfolio of herbicides and plant growth regulators for that crop. ## C. Biologicals & Biostimulants * **Regulatory Recovery:** A ban on biostimulants caused a significant revenue loss of over **₹50 Cr** in FY26; however, management expects a full recovery by 2026 as the market stabilizes under new regulations. * **Product Expansion:** Following the launch of **one molecule** last year, the company plans to introduce **three additional molecules** in June 2026 to capture share in the **₹4,000–₹5,000 Cr** Indian biological market. * **Climate Resilience:** The Mycorrhiza-based product (MYCOR-e SUPER) is positioned for increased demand specifically during El Niño or drought conditions. ## D. Bayer Partnership & Global Expansion * **Acquisition Ramp-up:** Revenue from the Triadimenol and Iprovalicarb acquisition is in a transition phase; full sales contribution is anticipated in the next financial year as Bayer exits commercialization. * **Export Footprint:** Dhanuka has already secured customers in **five countries** and is negotiating with **10 additional markets** for the acquired Bayer portfolio. * **Manufacturing Strategy:** To optimize the supply chain, the company will manufacture the active ingredient for **one** acquired molecule in-house while outsourcing the second. --- # 3. Manufacturing & Supply Chain ## A. Key Figures * **Dahej Facility EBITDA:** **-₹13 Cr** FY26 (vs. -₹14 Cr YoY) * **Infrastructure Scale:** **4** Manufacturing Facilities · **41** Warehouses · **2** R&D Centers ## B. Dahej Facility & Strategic Integration * **Insourcing & Backward Integration:** Shifting production of acquired portfolios (Melody, Triadimenol, Iprovalicarb) from Europe to India to capture cost arbitrage and improve capacity utilization. * **Revenue Performance Gap:** Annual revenue growth at Dahej was supported by new product launches and domestic Bifenthrin sales, though total turnover fell short of the **₹65 Cr** initial forecast. * **International Expansion:** Commenced first international sales following year-end registration; however, near-term volumes remain constrained by lengthy registration timelines in major global markets. ## C. Supply Chain & Operational Strategy * **Agile Inventory Management:** Production and logistics are executed in **small batches** to prioritize market responsiveness over economies of scale, allowing rapid adjustment to weather-driven demand shifts. * **Input Security:** Reported stable availability of technical materials from Japan and China, de-risking the supply chain for the upcoming Kharif season. * **Distribution Ramp-up:** Focus has shifted from registration hurdles to optimizing distributor appointments and supply chain logistics, supported by Bayer’s transition framework. ## D. Technology & Innovation * **R&D Infrastructure:** Growth pipeline is anchored by NABL-accredited labs and global innovator partnerships across Japan, Europe, and the U.S. to drive formulation development. --- # 4. Market & Customer Reach ## A. Key Figures * **Distribution Reach:** **1 Cr+** Farmers · **~6,000** Distributors · **80,000+** Retailers * **Regional Revenue Mix:** **33%** South · **32%** North · **23%** West · **12%** East * **Input Cost Inflation:** **3% to 5%** Raw Material Basket * **Pricing Actions:** **~2%** Q1 Increase · **3% to 4%** Anticipated Q2 Hike ## B. Customer Metrics * **Pan-India Footprint:** Maintains a massive distribution scale supported by a mission-driven focus on the Indian farming community. * **Knowledge Partnerships:** Sustains technology dissemination through strategic collaborations with agricultural universities and scientific institutions. ## C. Demand & Pricing * **Pricing Strategy:** Management is implementing phased price hikes to offset raw material inflation, with full pass-through targeted by the start of **Quarter 2**. * **Inventory & Placement:** Q4 product placement remained consistent with historical norms; healthy movement in the Rabi season suggests no excessive channel inventory. * **Demand Drivers:** Strong herbicide pull in North India driven by sugarcane; however, current market pull is a mix of end-consumer demand and channel speculative buying. * **Crop Economics:** Rising soybean prices (up to **₹65-₹70/kg**) and maize’s drought tolerance are influencing farmer planting decisions. ## D. Industry Trends * **Acreage Outlook:** Favorable price trends are expected to drive higher acreages for cotton, pulses, and oilseeds in the upcoming Kharif season. * **Labor Substitution:** Persistent labor shortages are accelerating the structural shift toward herbicide consumption, with West Bengal identified as the next growth frontier. * **Biofuel Tailwinds:** Maize acreage is projected to hold steady, supported by its critical role in bioethanol production. ## E. Strategic Initiatives * **Growth Roadmap:** Future scaling is centered on portfolio strengthening and enhancing integrated capabilities across R&D, manufacturing, and market development. --- # 5. Capital Allocation & Governance ## A. Key Figures * **Dividend:** **₹2.00** per share (100% of face value) · **₹9.02 Cr** total absorption * **Share Buyback:** **5 Lakh** shares (Max volume) · **₹1,400** per share (Max price) · **₹70 Cr** total outlay * **Buyback Premium:** **25%** over prevailing market price ## B. Shareholder Returns * **Consistent Payout Strategy:** Management maintained a significant premium for the buyback, mirroring the logic of the previous year's **₹2,000** offer to ensure attractive shareholder participation. * **Capital Efficiency Proposal:** Investors suggested utilizing open market purchases to fulfill **ESOP obligations** to avoid dilution, citing current valuation levels as a strategic entry point. ## C. M&A & Partnerships * **Strategic Alliance Termination:** The company has formally called off its biological products MoU with a Spanish partner. * **Risk Mitigation:** Management opted to abandon a potential partnership due to identified **red flags** and an impending change in ownership at the counterparty level. ## D. Leadership & Board * **Incentive Alignment:** The Board approved a new **Employee Stock Option Plan (ESOP)** designed to drive an entrepreneurial culture and secure long-term leadership. * **Organizational Transition:** The leadership team is steering a transition focused on integrating legacy strengths with increased agility and innovation. --- # 6. Risks & Agricultural Factors ## A. Key Figures * **Input Price Inflation:** **5% to 6%** on imported materials (Rupee depreciation) · **15% to 30%** on indigenous generic materials ## B. Market & Environmental Risks * **Climatic & Macro Headwinds:** Erratic weather patterns and unseasonal rainfall impacted Rabi sowing sentiment, while global supply chain volatility was exacerbated by conflict in the **Gulf region**. * **Structural Labor Shifts:** A persistent farm-level labor shortage is expanding into historically surplus regions (Bihar, Chhattisgarh) due to competing government and private sector **CapEx initiatives**. * **Seasonal Uncertainty:** While Kharif inventory is secured, management cited difficulty in predicting Rabi season outcomes if the current trend of rising input costs persists. ## C. Operational & Financial Risks * **Export Channel Friction:** Expansion into the new chemical business faces hurdles in establishing international distribution and securing regulatory approvals in global markets. * **Distributor Pricing Pressure:** International distributors are struggling to commit to required volumes or maintain price levels, often pushing for unworkable lower price points. * **Cost Inflation:** Significant double-digit spikes in indigenous material costs and mid-single-digit increases in imports are creating a challenging margin environment. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **Lower double-digit** FY '27 (Price growth > Volume by **~2%**) * **EBITDA Margin Guidance:** **100 bps** decline YoY * **Gross Margin Target:** **25-26%** current FY * **Biostimulant Revenue Target:** **>₹130 Cr** FY '27 ## B. Revenue & Operational Outlook * **Strategic Target Revision:** Management moderated the top-line outlook for the Dahej facility despite expecting significant year-over-year scaling. * **Near-Term Catalysts:** Strong Q1 momentum anticipated, specifically in June, leveraged by favorable monsoon forecasts and high acreage for oilseed pulses supporting the weedicide portfolio. * **Segment Recovery:** The biostimulant and biological category is projected to rebound in the next fiscal year, serving as a key growth pillar. ## C. Margin & Financial Headwinds * **Profitability Pressures:** Anticipated margin contraction is primarily attributed to the cessation of **GST refunds** and a reduction in **net economic benefits**. * **Fiscal Impact:** Financials face a **₹40 Cr** headwind from the loss of tax incentives, which the company aims to mitigate through the reintroduction of biostimulants. * **Inventory Dynamics:** Gross margins are being managed by balancing low-cost inventory and sourcing efficiencies against the phased impact of high-cost stock. ## D. Growth Opportunities * **Structural Resilience:** Despite monsoon and reservoir level uncertainties, a robust balance sheet supports a positive outlook on long-term structural opportunities in Indian agriculture.